These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33449439)

  • 1. Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.
    Farhan N; Cristofoletti R; Basu S; Kim S; Lingineni K; Jiang S; Brown JD; Fang LL; Lesko LJ; Schmidt S
    CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):199-210. PubMed ID: 33449439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.
    Wang N; Chen L; Li N; Xu G; Qi F; Zhu L; Liu W
    Sci Rep; 2020 Jun; 10(1):9717. PubMed ID: 32546773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
    Martin JL; Esmaeili H; Manuel RC; Petrini M; Wiebe S; Maas H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):399-406. PubMed ID: 29695165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
    Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y; Hu ZY
    Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
    Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
    Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.
    Moj D; Maas H; Schaeftlein A; Hanke N; Gómez-Mantilla JD; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1577-1593. PubMed ID: 31104266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
    Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
    Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model.
    Udomnilobol U; Dunkoksung W; Sakares W; Jianmongkol S; Prueksaritanont T
    Front Pharmacol; 2024; 15():1356273. PubMed ID: 38515840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate.
    Hattori T; Imaoka A; Akiyoshi T; Ohtani H
    Biopharm Drug Dispos; 2019 Nov; 40(9):315-324. PubMed ID: 31642538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
    J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C; Finsterer J
    Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
    Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
    Terayama Y
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
    Skripka A; Sychev D; Bochkov P; Shevchenko R; Krupenin P; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
    High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):151-156. PubMed ID: 32215878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.